Outcomes after treatment with proton pump inhibitors in patients with ineffective esophageal motility: a systematic review
Abstract
Aim: This systematic review evaluated the effectiveness of proton pump inhibitors (PPIs) in improving manometric parameters in patients with gastroesophageal reflux disease (GERD) diagnosed with Ineffective esophageal motility (IEM). Background: IEM represents the most common esophageal motility disorder among patients with GERD. To date, no treatment has conclusively demonstrated efficacy in restoring esophageal motor function in these individuals. Methods: This systematic review was performed according to the PRISMA guidelines. We conducted comprehensive searches of electronic databases, including PubMed, Embase, and Scopus, until January 2024 to identify relevant randomized and non-randomized controlled trials. Criteria for study inclusion were based on the population, intervention, comparison, and outcome framework. Results: A total of 9 studies met the inclusion criteria, comprising eight non-randomized controlled trials (non-RCTs) and one randomized controlled trial (RCT). Out of 305 recruited patients with a diagnosis of GERD, 185 patients matched the diagnosis of IEM with manometric studies before and after a PPI treatment. PPIs used in the studies included omeprazole, pantoprazole, lansoprazole, and rabeprazole. The duration of treatment ranged from four to twenty-four weeks. Except for one study, there was no statistically significant improvement in manometric parameters following PPI treatment. Conclusion: Evidence from included studies indicates that although…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 305 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.